Last reviewed · How we verify
Carbocaine — Competitive Intelligence Brief
marketed
Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha
Pain
Small molecule
Live · refreshed every 30 min
Target snapshot
Carbocaine (Carbocaine) — Nantes University Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Carbocaine TARGET | Carbocaine | Nantes University Hospital | marketed | Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Carbocaine CI watch — RSS
- Carbocaine CI watch — Atom
- Carbocaine CI watch — JSON
- Carbocaine alone — RSS
Cite this brief
Drug Landscape (2026). Carbocaine — Competitive Intelligence Brief. https://druglandscape.com/ci/carbocaine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing